Project Grant F31DA062489
Award Date
9/25/25
Completion Date
Not listed
Dollars Obligated
$49K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,076,036 to the University of Pittsburgh to conduct research on targeting prefrontal cortex (PFC) interneurons for personalized treatments in opioid use disorder (OUD). The key objectives are to: Assess how individual differences in PFC theta power and interneuron physiology correlate with fentanyl self-administration and affective disturbances...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $759,339 to The Trustees of the University of Pennsylvania to conduct research on the role of central amylin receptors in opioid-mediated behaviors. The key objectives are to: Comprehensively define the functional roles of cell type-specific ventral tegmental area (VTA) and nucleus accumbens (NAc) amylin receptors in opioid taking and seeking behaviors...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This $403,542 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to profile projection-specific proteome associated with the incubation of oxycodone craving. The project will focus on the orbitofrontal cortex (OFC) to dorsal striatum (DS) projections, analyzing proteome changes in OFC neuronal somas (Aim 1) and OFC-DS projection-specific synaptoneurosomes in the DS (Aim 2) during the incubation of oxycodone...
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,285,443 to Virginia Commonwealth University (VCU) to conduct a mechanistic study investigating the role of the orexin system in treating opioid use disorder (OUD) and comorbid insomnia. The key products and services to be delivered under this 5-year award include: 1) Examining the effects of the FDA-approved dual orexin receptor antagonist...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $147,486 to The Trustees of the University of Pennsylvania to conduct research on the role of mu-opioid receptor (MOR)-expressing neurons in the paraventricular nucleus of the thalamus (PVT) in the development of stress-related phenotypes and their influence on opioid self-administration. The key objectives are to: a) determine how susceptible and resilient...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA program "Drug Use and Addiction Research Programs" (93.279), will support research to uncover the neurophysiological signatures within the addiction circuitry related to acute opioid use. The $159,711 award, effective January 1, 2025 through December 31, 2029, will leverage a unique ability to directly record local field potentials from awake humans with implanted brain electrodes. This will...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...